---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031669"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:47:33.922276+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DiaMedica amends ReMEDy2 stroke trial protocol; cash $56.2M with runway to 2026

## Summary
- FDA 30-day review of protocol amendments passed without comment; changes focus on moderate anterior circulation strokes (NIHSS 5-15).
- Initial US clinical site activations expected in Nov-Dec 2023; full enrollment for interim analysis targeted by 2024.
- Cash and investments $56.2M as of Sep 30, 2023, up from $33.5M at Dec 31, 2022; cash runway into 2026.
- Q3 2023 R&D expenses $3.3M (vs $1.6M Q3 2022); G&A $1.9M (vs $1.5M); net cash used in operations $14.9M for nine months (vs $8.7M prior).

## SEC filing metadata
- accession: 0001437749-23-031669
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774923031669/0001437749-23-031669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774923031669/dmtp20231112_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031669
- JSON: https://secwatch.observer/filing/0001437749-23-031669.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031669.txt

## Key facts
- Earnings Releases
  DiaMedica Therapeutics Inc. reported financial results for three and nine-month periods ended September 30, 2023.
  - Period: three and nine-month periods ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the three and nine-month periods ended September 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference and constitutes a part of Item 2.02 of this report.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774923031669/0001437749-23-031669-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.